Danish pharmaceutical, which manufactures Ozempic, signs a $ 2 billion agreement with United Lab
New Danish Nordisk has acquired the global rights of UBT251, an experimental weight loss drug from China.
The agreement has a potential value of up to $ 2 billion and is part of the pharmaceutical strategy to consolidate its leadership in the obesity market, valued at US $ 150 billion.
Novo Nordisk is recognized for its portfolio in diabetes and obesity -and manufacturer of Ozempic and Wegovy. The company has sought to expand its performance in the obesity segment through the development of new medicines, acquisitions and partnerships. The acquisition of United Lab’s UBT251 allows the new Nordisk to develop, manufacture and market treatment.
UBT251 is a medicine that acts on a new class, which effects in the intestine and pancreas hormones. This can result in a higher weight loss than current medications that focus only on the LPG-1 hormone. UBT251 targets GLP-1, GIP and GLUCAGON, being called “triple G”.
Development emerges in a challenging moment for the new Nordisk. The company faced disappointing results with Cagrisema, one of its obesity medicines.
